Free Trial

Merus (MRUS) Stock Price, News & Analysis

Merus logo
$94.88 +0.46 (+0.49%)
Closing price 04:00 PM Eastern
Extended Trading
$94.65 -0.23 (-0.24%)
As of 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Merus Stock (NASDAQ:MRUS)

Advanced

Key Stats

Today's Range
$94.40
$95.06
50-Day Range
$63.65
$94.95
52-Week Range
$33.19
$95.06
Volume
2.51 million shs
Average Volume
5.19 million shs
Market Capitalization
$7.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$93.12
Consensus Rating
Hold

Company Overview

Merus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

MRUS MarketRank™: 

Merus scored higher than 36% of companies evaluated by MarketBeat, and ranked 746th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Merus has received a consensus rating of Hold. The company's average rating score is 2.16, and is based on 4 buy ratings, 14 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Merus is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Merus has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Merus' stock forecast and price target.
  • Earnings Growth

    Earnings for Merus are expected to decrease in the coming year, from ($3.85) to ($4.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Merus is -17.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Merus is -17.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Merus has a P/B Ratio of 10.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Merus' valuation and earnings.
  • Percentage of Shares Shorted

    3.83% of the outstanding shares of Merus have been sold short.
  • Short Interest Ratio / Days to Cover

    Merus has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Merus has recently decreased by 33.03%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Merus does not currently pay a dividend.

  • Dividend Growth

    Merus does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.83% of the outstanding shares of Merus have been sold short.
  • Short Interest Ratio / Days to Cover

    Merus has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Merus has recently decreased by 33.03%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Merus has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Merus this week, compared to 8 articles on an average week.
  • Search Interest

    12 people have searched for MRUS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Merus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Merus insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.70% of the stock of Merus is held by insiders.

  • Percentage Held by Institutions

    96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Merus' insider trading history.
Receive MRUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRUS Stock News Headlines

Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
Merus N.V. (NASDAQ:MRUS) Receives Average Rating of "Hold" from Analysts
See More Headlines

MRUS Stock Analysis - Frequently Asked Questions

Merus' stock was trading at $42.05 at the beginning of 2025. Since then, MRUS stock has increased by 125.6% and is now trading at $94.88.

Merus N.V. (NASDAQ:MRUS) announced its quarterly earnings data on Tuesday, August, 5th. The biotechnology company reported ($2.23) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by $1.06. The biotechnology company earned $8.83 million during the quarter, compared to the consensus estimate of $9.77 million. Merus had a negative net margin of 685.64% and a negative trailing twelve-month return on equity of 50.28%.

Merus (MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Top institutional investors of Merus include Voya Investment Management LLC (0.28%), Moody Aldrich Partners LLC (0.10%), Simplify Asset Management Inc. (0.04%) and Tema Etfs LLC (0.04%). Insiders that own company stock include Sven Ante Lundberg, Harry Shuman and Peter B Silverman.
View institutional ownership trends
.

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Merus investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE), Jabil (JBL) and Disc Medicine (IRON).

Company Calendar

Last Earnings
8/05/2025
Today
10/24/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRUS
CIK
1651311
Fax
N/A
Employees
37
Year Founded
2003

Price Target and Rating

High Price Target
$110.00
Low Price Target
$70.00
Potential Upside/Downside
-1.9%
Consensus Rating
Hold
Rating Score (0-4)
2.16
Research Coverage
19 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$215.33 million
Net Margins
-685.64%
Pretax Margin
-670.59%
Return on Equity
-50.28%
Return on Assets
-42.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.39
Quick Ratio
8.39

Sales & Book Value

Annual Sales
$36.13 million
Price / Sales
198.61
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.46 per share
Price / Book
10.03

Miscellaneous

Outstanding Shares
75,630,000
Free Float
72,836,000
Market Cap
$7.18 billion
Optionable
Optionable
Beta
1.26

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:MRUS) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners